Abstract
ABSTRACTIntestinal mucin acts as a barrier protecting the infant gut wall against diseases such as colitis and rotavirus.In vitroexperiments have shown that the gut microbiota of breastfed infants consumes less mucin than the microbiota of non-breastfed infants, but the mechanisms are incompletely understood. The main difference between human milk and most infant formulas is the presence of human milk oligosaccharides (HMOs) in human milk. We hypothesize that HMOs protect mucin by stimulating non-mucin consuming bacteria. To understand the un-derlying mechanisms we developed a computational model that describes the metabolism and ecology of the infant gut microbiota. Model simulations suggest that extracellular digestion of the HMO 2’-fucosyllactose by the mucin-consumerBifidobacterium bifidummay make this species vulnerable to competitors. The digestion products of HMOs become ‘public goods’ that can be consumed by competing species such asBacteroides vulgatusinstead.Bifidobacterium longum, which does not consume mucin or produce public goods, can then become dominant, despite growing less efficiently on HMOs in monocultures thanB. bifidum. In conclusion, our model simulations suggest that, through complex ecological interactions, HMOs may help lower mucin consumption by stimulating the non-mucin consumerB. longumat the expense of the mucin consumerB. bifidum.
Publisher
Cold Spring Harbor Laboratory